
Agilon Health (AGL) Stock Forecast & Price Target
Agilon Health (AGL) Analyst Ratings
Bulls say
Agilon Health Inc demonstrated significant growth, with total revenue increasing by 44.2% year-over-year in the fourth quarter, surpassing initial estimates. The company's Medicare Advantage (MA) membership expanded by 36% year-over-year, reaching 527,000 members, supported by a 4.1% growth in the same geography during the quarter. Improvements in medical cost data and operating expenses, which came in lower than expected, further underlie the company's positive trajectory and potential for sustainable financial performance.
Bears say
Agilon Health has demonstrated ongoing visibility issues, particularly evident in the second half of the year, which resulted in negative surprises regarding financial forecasts due to challenges with utilization. In the fourth quarter of 2024, the company reported an adjusted EBITDA loss of $(84.0) million, falling short of expectations and reflecting lower medical margins, notably a significant decrease from prior estimates. Additionally, the guidance for ACO REACH patients projected a 12.9% to 20.5% quarter-over-quarter decline, signaling potential challenges in growth and margins that contribute to an overall negative financial outlook.
This aggregate rating is based on analysts' research of Agilon Health and is not a guaranteed prediction by Public.com or investment advice.
Agilon Health (AGL) Analyst Forecast & Price Prediction
Start investing in Agilon Health (AGL)
Order type
Buy in
Order amount
Est. shares
0 shares